Fresh from the Pipeline | Published:

Sipuleucel-T

Nature Reviews Drug Discovery volume 9, pages 513514 (2010) | Download Citation

Abstract

In April 2010, sipuleucel-T (Provenge; Dendreon), an autologous cellular immunotherapy, was approved by the US FDA for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. It is the first therapeutic cancer vaccine to receive FDA approval.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Cancer statistics, 2009. CA Cancer J. Clin. 59, 225–249 (2009).

  2. 2.

    & Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer. Nature Clin. Pract. Oncol. 5, 506–507 (2008).

  3. 3.

    & Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. Ann. Pharmacother. 42, 91–98 (2008).

  4. 4.

    The promise of cancer vaccines. Nature Rev. Cancer 4, 401–411 (2004).

  5. 5.

    US Food and Drug Administration. FDA labelling information — Provenge. FDA website , (2010).

  6. 6.

    et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol. 18, 3894–3903 (2000).

  7. 7.

    et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin. Cancer Res. 6, 2175–2182 (2000).

  8. 8.

    et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24, 3089–3094 (2006).

  9. 9.

    et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502–1512 (2004).

  10. 10.

    et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351, 1488–1490 (2004).

  11. 11.

    et al. Randomized trial of active cellular immunotherapy with sipuleucel-T in androgen dependent prostate cancer (ADPC). J. Clin. Oncol. 25, 18S (2007).

  12. 12.

    et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401. J. Clin. Oncol. 28, 344s (2010).

  13. 13.

    IMS MIDAS (2009).

  14. 14.

    & Biotechnology equity research report. Wells Fargo Securities (19 May 2010).

  15. 15.

    , & Equity research report. JP Morgan North America (11 May 2010).

Download references

Author information

Affiliations

  1. Celestia S. Higano is at the Department of Medicine, University of Washington and Fred Hutchinson Cancer Research Center, USA.  thigano@u.washington.edu

    • Celestia S. Higano
  2. Eric J. Small is at the Department of Medicine and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, USA.

    • Eric J. Small
  3. Paul Schellhammer is at the Department of Urology, Eastern Virginia Medical School, USA.

    • Paul Schellhammer
  4. Uma Yasothan and Steven Gubernick are at IMS Health, 7 Harewood Avenue, London NW1 6JB, UK.  UYasothan@de.imshealth.com

    • Uma Yasothan
    •  & Steven Gubernick
  5. Peter Kirkpatrick is at Nature Reviews Drug Discovery.  p.kirkpatrick@nature.com

    • Peter Kirkpatrick
  6. Philip W. Kantoff is at the Department of Medicine, Dana–Farber Cancer Institute, Harvard Medical School, USA.  Philip_Kantoff@dfci.harvard.edu

    • Philip W. Kantoff

Authors

  1. Search for Celestia S. Higano in:

  2. Search for Eric J. Small in:

  3. Search for Paul Schellhammer in:

  4. Search for Uma Yasothan in:

  5. Search for Steven Gubernick in:

  6. Search for Peter Kirkpatrick in:

  7. Search for Philip W. Kantoff in:

Competing interests

The authors declare no competing financial interests.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrd3220

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing